Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993217priorityCriticalpatent/ECSP993217A/en
Publication of ECSP993217ApublicationCriticalpatent/ECSP993217A/en
Investigating Or Analysing Biological Materials
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Un método para el tratamiento de diabetes mellitus de tipo 2 y condiciones asociadas con diabetes mellitus, cuyo método comprende la administración de una cantidad eficaz y no tóxica de un sensibilizador de insulina a un mamífero humano o no humano con necesidad de ello, con objeto de proporcionar una concentración plásmática umbral dentro del intervalo de niveles plasmáticos eficaces del sesibilizador de insulina, composiciones para el uso de dicho método y metodologia para determinar concentraciones plasmáticas de agente activo para uso en tales métodos.A method for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises administering an effective and non-toxic amount of an insulin sensitizer to a human or non-human mammal in need thereof, in order to to provide a threshold plasma concentration within the range of effective plasma levels of the insulin sesibilizer, compositions for use of said method, and methodology for determining plasma concentrations of active agent for use in such methods.
ECSP9932171999-11-121999-11-12
NEW TREATMENT METHOD VII
ECSP993217A
(en)
Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject.